Association of combined fractional excretion of phosphate and FGF23 with heart failure and cardiovascular events in moderate and advanced renal disease
L Mendonça, M Bigotte Vieira, JS Neves - Journal of Nephrology, 2023 - Springer
Background High levels of FGF23 associate with adverse events in CKD. The urinary
fractional excretion of phosphate (FePi) might modify this association, although data are …
fractional excretion of phosphate (FePi) might modify this association, although data are …
FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment
S Seiler, B Reichart, D Roth, E Seibert… - Nephrology Dialysis …, 2010 - academic.oup.com
Background. High levels of the phosphaturic hormone fibroblast growth factor 23 (FGF-23)
predict mortality in haemodialysis patients. The prognostic relevance of increased plasma …
predict mortality in haemodialysis patients. The prognostic relevance of increased plasma …
Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH …
T Shigematsu, S Negi… - Nephrology Dialysis …, 2012 - academic.oup.com
Background. Increased blood levels of fibroblast growth factor-23 (FGF-23) are associated
with increased mortality. We evaluated the effect of combined therapy with lanthanum …
with increased mortality. We evaluated the effect of combined therapy with lanthanum …
[HTML][HTML] Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival …
JM Frazao, T Adragao - Kidney International, 2008 - Elsevier
In chronic kidney disease patients, bone and mineral abnormalities have a major impact on
morbidity and mortality. Hyperphosphatemia has been associated with increased mortality …
morbidity and mortality. Hyperphosphatemia has been associated with increased mortality …
A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD …
S Fishbane, J Delmez, WN Suki, SK Hariachar… - American journal of …, 2010 - Elsevier
BACKGROUND: Sevelamer carbonate powder for oral suspension is a new dosage form of
sevelamer, which may be suited to once-daily dosing. STUDY DESIGN: Randomized …
sevelamer, which may be suited to once-daily dosing. STUDY DESIGN: Randomized …
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
M Ketteler, SM Sprague, AC Covic… - Nephrology Dialysis …, 2019 - academic.oup.com
Background Treatment of hyperphosphataemia is the primary goal of chronic kidney disease–
mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a …
mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a …
Fibroblast growth factor 23 as a risk factor of left ventricular hypertrophy and vascular calcification in predialysis chronic kidney disease patients
Objective The objective of this study was to evaluate the possible role of fibroblast growth
factor 23 (FGF23) in the occurrence of left ventricular hypertrophy and vascular calcification …
factor 23 (FGF23) in the occurrence of left ventricular hypertrophy and vascular calcification …
Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease
AL Negri - International urology and nephrology, 2014 - Springer
Abstract Fibroblast growth factor-23 (FGF-23) has emerged as an important hormone
involved in phosphorus and vitamin D homeostasis. Chronic kidney disease (CKD) is the …
involved in phosphorus and vitamin D homeostasis. Chronic kidney disease (CKD) is the …
Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised …
CD Chue, JN Townend, RP Steeds, CJ Ferro - Trials, 2011 - Springer
Background Serum phosphate is an independent predictor of cardiovascular morbidity and
mortality in patients with chronic kidney disease and the general population. There is …
mortality in patients with chronic kidney disease and the general population. There is …
[HTML][HTML] Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
T Isakova, P Wahl, GS Vargas, OM Gutiérrez… - Kidney international, 2011 - Elsevier
Fibroblast growth factor 23 (FGF23) regulates phosphorus metabolism and is a strong
predictor of mortality in dialysis patients. FGF23 is thought to be an early biomarker of …
predictor of mortality in dialysis patients. FGF23 is thought to be an early biomarker of …